Testing effectiveness (Phase 2)WithdrawnNCT03005639What this trial is testingML29255 Neoadjuvant Vemurafenib and Cobimetinib MelanomaWho this might be right forStage IIIB-C Melanoma Inova Health Care Services
Early research (Phase 1)WithdrawnNCT04759846What this trial is testingHepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF MelanomaWho this might be right forBRAF V600 MutationUnresectable MelanomaMetastatic Melanoma+1 more Pierre Fabre Medicament
Testing effectiveness (Phase 2)Ended earlyNCT01495988What this trial is testingTrial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant MelanomaWho this might be right forMelanomaMetastatic Melanoma Melanoma Research Foundation Breakthrough Consortium 10
Large-scale testing (Phase 3)Study completedNCT01245062What this trial is testingGSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive MelanomaWho this might be right forMelanoma GlaxoSmithKline 322
Early research (Phase 1)Looking for participantsNCT04903119What this trial is testingNilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic MelanomaWho this might be right forMetastatic MelanomaBRAF Gene Mutation Rina Plattner 30
Early research (Phase 1)Study completedNCT01351103What this trial is testingLGK974 in Patients With Malignancies Dependent on Wnt LigandsWho this might be right forPancreatic CancerBRAF Mutant Colorectal CancerMelanoma+5 more Novartis Pharmaceuticals 185
Testing effectiveness (Phase 2)WithdrawnNCT02263898What this trial is testingIntermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 MutationsWho this might be right forRecurrent MelanomaStage IV Melanoma Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT04417621What this trial is testingStudy of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaWho this might be right forMelanoma Novartis Pharmaceuticals 134
Early research (Phase 1)Study completedNCT03415126What this trial is testingASN007 in Patients With Advanced Solid TumorsWho this might be right forCancerMalignancyNeoplasia+16 more Asana BioSciences 49
Large-scale testing (Phase 3)Study completedNCT01667419What this trial is testingVemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant MelanomaWho this might be right forMelanoma Hoffmann-La Roche 498
Early research (Phase 1)Ended earlyNCT01940809What this trial is testingIpilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by SurgeryWho this might be right forBRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Melanoma+5 more National Cancer Institute (NCI) 15
Early research (Phase 1)WithdrawnNCT02915666What this trial is testingA Clinical Trial of Patients With MelanomaWho this might be right forMelanoma University of Texas Southwestern Medical Center
Not applicableStudy completedNCT04911998What this trial is testingA Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma PatientsWho this might be right forMelanoma (Skin)Metastatic MelanomaBRAF V600 Mutation Pierre Fabre Medicament 400
Testing effectiveness (Phase 2)Looking for participantsNCT06887088What this trial is testingEncorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain MetastasesWho this might be right forMelanoma BRAF V600E/K MutatedMelanoma and Brain Metastases Grupo Español Multidisciplinar de Melanoma 33
Testing effectiveness (Phase 2)Study completedNCT01072175What this trial is testingInvestigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212Who this might be right forCancer Novartis Pharmaceuticals 430
Testing effectiveness (Phase 2)Ended earlyNCT03391050What this trial is testingAPR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant MelanomaWho this might be right forMelanoma Aprea Therapeutics 3
Testing effectiveness (Phase 2)Study completedNCT01726738What this trial is testingLCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional MutationsWho this might be right forStage III MelanomaStage IV MelanomaUnresectable Melanoma+1 more UNC Lineberger Comprehensive Cancer Center 17
Early research (Phase 1)Ended earlyNCT03272464What this trial is testingINCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.Who this might be right forMelanoma Massachusetts General Hospital 1
Early research (Phase 1)Study completedNCT01436656What this trial is testingA Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant MelanomaWho this might be right forMelanoma and Metastatic Colorectal Cancer Pfizer 107
Testing effectiveness (Phase 2)UnknownNCT02036086What this trial is testingStudy of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node MetastasesWho this might be right forMelanoma Sunnybrook Health Sciences Centre 24